NASDAQ : GRTS

Gritstone bio, Inc.

$0.0322 USD

-$0.01 (-31.78%)

Volume
55.25M
Average Volume
17.68M
Market Capitalization
$3.8M
P/E Ratio
-0.03
Dividend Yield
0.00%
Price Target
$5.00
Year High
$3.17
Year Low
$0.03
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.20
Company Overview

NASDAQ

Andrew R. Allen BCh, BM, MA, MRCP,

Biotechnology

Healthcare

GRTS

231

US

USD

https://nexoplexbio.com

510 871 6100

39868T105

0001656634

Liquidity Metrics

2.02

3.20

3.20

2.39

0.00

Sales & Valuation

$1.33M

2.86

0.07

-0.03

-1.09

Profitability

-$1.2

-$138.49M

-10404.96%

-10404.96%

-124.41%

-77.90%

P/E Metrics

-0.03

0.00

0.00

Analyst Price Target & Rating

$5.00

$6.00

$3.00

N/A

0/5

13 Analysts

-99.36%

Financial Health Scores

-9.73

1/9

$36.81M

$142.54M

$120.35M

-$128.22M

Key Metrics (TTM)

$43.29M

32.53

-0.34

3.20

-124.41%

-94.15%

-3722.86%

-3318.86%

-120 days

Company Executives
Name Title
Karin Jooss Executive Vice President and Head of Research & Development
Andrew R. Allen BCh Co-Founder, President, Chief Executive Officer & Director
Matthew Hawryluk Executive Vice President & Chief Business Officer
George MacDougall Director of Investor Relations & Corporate Communications
James Cho Chief Accounting Officer
Stacy Proctor Executive Vice President & Chief People Officer
Vassiliki Economides Executive Vice President & Chief Financial Officer
Erin E. Jones Executive Vice President & Chief Operating Officer
Poll Results

No votes yet today — be the first to share your view!

About Gritstone bio, Inc. (NASDAQ:GRTS) Stock

Gritstone bio, Inc. is a clinical-stage biotechnology company focused on pioneering immunotherapies to address various types of cancer and infectious diseases. Its primary product candidate, GRANITE, is a neoantigen-based immunotherapy designed to treat a range of solid tumors, specifically including metastatic non-small cell lung cancer, gastroesophageal, bladder, and microsatellite stable colorectal cancers. Gritstone bio is also advancing SLATE, an off-the-shelf immunotherapy candidate aimed at common solid tumors such as metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and those with shared neoantigens. Furthermore, the company is developing CORAL, a SARS-CoV-2 vaccine platform intended to provide broader and more robust immunity against variants by deliveri ... ng both spike and additional SARS-CoV-2 T cell epitopes. It is also working on a therapeutic vaccine candidate focused on treating and potentially curing human immunodeficiency virus (HIV) infection. Gritstone bio maintains key partnerships, including a strategic collaboration with bluebird bio, Inc., a collaboration agreement with Gilead Sciences, Inc., and a license agreement with Genevant Sciences GmbH. Founded in 2015 and headquartered in Emeryville, California, the company operated as Gritstone Oncology, Inc. until its rebranding to Gritstone bio, Inc. in May 2021.

Frequently Asked Questions

What is the current Gritstone bio, Inc. (GRTS) stock price?

Gritstone bio, Inc.(NASDAQ:GRTS) stock price is $0.0322 in the last trading session. During the trading session, GRTS stock reached the peak price of $3.17 while $0.03 was the lowest point it dropped to. The percentage change in GRTS stock occurred in the recent session was --31.78% while the dollar amount for the price change in GRTS stock was -$0.01.

GRTS's industry and sector of operation?

The NASDAQ listed GRTS is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of GRTS?

Karin Jooss | Executive Vice President and Head of Research & Development
Andrew R. Allen BCh | Co-Founder, President, Chief Executive Officer & Director
Matthew Hawryluk | Executive Vice President & Chief Business Officer
George MacDougall | Director of Investor Relations & Corporate Communications
James Cho | Chief Accounting Officer

How many employees does GRTS have?

Number of GRTS employees currently stands at 231. GRTS operates from 5959 Horton Street, EmeryVille, CA 94608, US.

Link for GRTS official website?

Official Website of GRTS is: https://nexoplexbio.com

How do I contact GRTS?

GRTS could be contacted at phone #510 871 6100 and can also be accessed through its website. GRTS operates from 5959 Horton Street, EmeryVille, CA 94608, US.

How many shares of GRTS are traded daily?

The average number of GRTS shares traded daily for last 3 months was 17.68M.

What is the market cap of GRTS currently?

The market value of GRTS currently stands at $3.8M with its latest stock price at $0.0322